Traws Pharma, Inc. TRAW
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
-209.84
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $2.8M | $9.2M | — | — | -$629,000 |
| 2024 | $226,000 | -$166.5M | — | — | -$31.6M |
| 2023 | $226,000 | -$18.9M | — | -$17.9M | $10.7M |
| 2022 | $226,000 | -$19.0M | — | — | $28.3M |
| 2021 | $226,000 | -$16.2M | — | — | $46.1M |
| 2020 | $231,000 | -$25.2M | — | -$23.1M | $6.2M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -209.84 (distress)
- Working capital / assets -0.298
- Retained earnings / assets -60.279
- EBIT / assets -1.684
- Equity / liabilities -0.056
Source: SEC EDGAR filings · CIK 0001130598 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.